Donor viral specific T-cells for viral infections in immunocompromised patients

• Viral Specific VST Infusion

  Intervention · BIOLOGICAL

  VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following: * Blood adenovirus PCR ≥ 1,000 * Blood CMV PCR ≥ 500 * Blood EBV PCR ≥ 9,000 * Plasma BKV PCR >1,000 * Plasma JC Virus PCR > 1,000 * Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites * Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis * Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies * Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy * Evidence of PML or other CNS infection due to JC virus

Official title

Third Party Viral Specific T-cells (VSTs) for Treatment of Viral Infections in Immunocompromised Patients

Sponsor

Children's Hospital Medical Center, Cincinnati

Conditions

Viral Infection · Viral Reactivation · Infection in an Immunocompromised Host

Enrolling

1,000 people

Starts

2015-09-02

Est. completion

2029-12

Design

Open-label, single group, Phase 2

Record

View on ClinicalTrials.gov ↗

The sponsor hasn't published answers to common questions for this trial.